Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18898243 | 0.97 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL19841888 | 0.94 | CXCR4 (0.42) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL22154777 | 0.94 | CXCR4 (0.39) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL20284982 | 0.91 | ALDH1A1 (0.44) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL6012129 | 0.91 | — | — | |
| SCHEMBL13770430 | 0.88 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL939538 | 0.88 | CXCR4 (0.35) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL26460947 | 0.88 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL21390263 | 0.88 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL14789140 | 0.88 | ALDH1A1 (0.50) | CXCR4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002790-A1 | POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884118-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | MYOC, MTREX, SLC26A4 | CXCR4 449/4885SMN1; SMN2 2618/4885ALDH1A1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.